Drug Treatment of Canine Acral Lick: An Animal Model of Obsessive-compulsive Disorder

Archives of General Psychiatry

Volumn 49, Issue 7, 1992, Pages 517-521

  Rapoport, Judith L ^a   Ryland, David H ^a   Kriete, Martin ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NIH Animal Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; DESIPRAMINE; FENFLURAMINE; FLUOXETINE; PLACEBO; SERTRALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG EFFICACY; GROOMING; INFECTION; LETHARGY; LICKING; NEURODERMATITIS; NONHUMAN; OBSESSION; ORAL DRUG ADMINISTRATION; PHENOMENOLOGY; PRIORITY JOURNAL; SEROTONIN UPTAKE; ULCER;

1-NAPHTHYLAMINE; ANIMAL; CLOMIPRAMINE; DERMATITIS; DESIPRAMINE; DISEASE MODELS, ANIMAL; DOG DISEASES; DOGS; DOUBLE-BLIND METHOD; FENFLURAMINE; FLUOXETINE; FOLLOW-UP STUDIES; GROOMING; HUMAN; NEUROTRANSMITTER UPTAKE INHIBITORS; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN; SERTRALINE; ULCER;

EID: 0026695687     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1992.01820070011002     Document Type: Article

References (48)

1. Swedo S, Rapoport J, Cheslow D, Leonard H, Ayoub E, Hosier D, Wald E. High prevalence of obsessive-compulsive symptoms in patients with Sydenham's chorea. Am J Psychiatry. 1989;146: 246–249.
2. Wise S, Rapoport J. Obsessive-compulsive disorder: a basal ganglia disease? In: Rapoport J, ed. Obsessive-compulsive Disorder in Children and Adolescents. Washington, DC: American Psychiatric Press Inc; 1989: 327–346.
3. Rapoport J. Recent advances in obsessive-compulsive disorder. Neuropsychopharmacology. 1991;5: 1–10.
4. Jenike M. Drug treatment of obsessive-compulsive disorder. In: Jenike M, Baer L, Minichiello W, eds. Obsessive-compulsive Disorders: Theory and Treatment. 2nd ed. St Louis, Mo: Mosby—Year Book; 1990: 249–282.
5. Swedo S, Rapoport J, Leonard H, Lenane M, Cheslow D. Obsessive-compulsive disorder in children and adolescents: clinical phenomenology of 70 consecutive cases. Arch Gen Psychiatry. 1989;46: 335–341.
6. Lenane M, Swedo S, Leonard H, Pauls D, Sceery W, Rapoport J. Psychiatric disorders in first-degree relatives of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 1990;29: 407–412.
7. Rapoport J, ed. Obsessive-compulsive Disorder in Childhood and Adolescence. Washington, DC: American Psychiatric Press Inc; 1989.
8. Khanna S, Srinath S. Childhood obsessive-compulsive disorder. Psychopathology. 1988;21: 254–258.
9. Honjo S, Hirano C, Murase C, Kaneko T, Sugiyama T, Ohtaka K, Aoyama T, Takei Y, Inoko K, Wakabayashi S. Obsessive-compulsive symptoms in childhood and adolescence. Acta Psychiatr Scand. 1989;80: 83–91.
10. Swedo S, Leonard H, Rapoport J, Lenane M, Cheslow D, Goldberger E. Clomipramine vs desmethylimipramine treatment of trichotillomania: a double-blind comparison. N Engl J Med. 1989;321: 497–501.
11. Leonard HL, Lenane M, Swedo S, Rettew D, Rapoport J. A double-blind comparison of clomipramine and desipramine treatment of severe onychophagia (nail biting). Arch Gen Psychiatry. In press.
12. Swedo S. Rituals and releasers: an ethological model of obsessive-compulsive disorder. In: Rapoport J, ed. Obsessivecompulsive Disorder in Children and Adolescents. Washington, DC: American Psychiatric Press Inc; 1989: 269–289.
13. Pitman R. Animal models of compulsive behavior. Biol Psychiatry. 1989;26: 189–198.
14. Insel T, Winslow J, Neurobiology of obsessive-compulsive disorder. In: Jenike M, Baer L, Minichiello W, eds. Obsessive-compulsive Disorders: Theory and Management. 2nd ed. St Louis, Mo: Mosby—Year Book; 1990: 118–131.
15. Ricciardi J, Hurley E. Development of animal models of obsessive-compulsive behaviors. In: Jenike M, Baer L, Minichiello W, eds. Obsessive-compulsive Disorders: Theory and Treatment. 2nd ed. St Louis, Mo: Mosby—Year Book; 1990: 189–199.
16. Sandberg P, Emerich D. Neural basis of behavior: animal models of human conditions. Brain Res Bull. 1990;25: 447–451.
17. Muller G, Kirk R, Scott D. Psychogenic dermatoses. In: Muller G, Kirk R, Scott D, eds. Small Animal Dermatology. 3rd ed. Philadelphia, Pa: WB Saunders Co; 1983: 625–635.
18. Young MS, Manning TO. Psychogenic dermatosis. Dermatol Rep. 1984;3: 1–8.
19. Veith V. Behavioral disorders. In: Davis L, ed. Handbook of Small Animal Therapeutics. New York, NY: Churchill Livingstone Inc; 1985: 519–535.
20. Veith L. Acral lick dermatitis in the dog. Canine Pract. 1986;3: 15–22.
21. Goldberger E, Rapoport J. Canine acral lick dermatitis: response to the anti-obsessional drug clomipramine. J Am Anim Hosp Assoc. 1991;22: 179–182.
22. Zohar J. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment and pathophysiology. Biol Psychiatry. 1987;22: 667–687.
23. Piggott T, Zohar J, Hill H, Berstein S, Grover G, Zohar-Kaduch R, Murphy D. Metergoline blocks and behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder. Biol Psychiatry. 1991;29: 418–426.
24. SAS Institute. User's Guide: Statistics Version 5. Cary, NC: SAS Institute; 1985.
25. Green A. Neuropharmacology of Serotonin. New York, NY: Oxford University Press Inc; 1985.
26. Sanders-Bush E, ed. The Serotonin Receptors. Clifton, NJ: Humana Press; 1988.
27. Jacobs B, Wilkinson L, Fornal C. The role of brain serotonin: a neurophysiologic perspective. Neuropsychopharmacology. 1990;3: 473–479.
28. Hollander E, Fay M, Cohen B, Campeas R, Gorman J, Liebowitz M. Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioral findings. Am J Psychiatry. 1988;145: 1015–1017.
29. McBride PA, DeMaeo MD, Sweeney JA, Halper J, Mann JJ, Shear MK. Neuroendocrine and behavioral responses to challenge with the indirect serotonin agonist dl-fenfluramine in adults with obsessive-compulsive disorder. Biol Psychiatry. 1992;31: 19–34.
30. Caccia S, Ballabio G, Guiso M, Rocchetti, Garattini S. Species differences in the kinetics and metabolism of fenfluramine isomers. Arch Int Pharmacodyn Ther. 1982;258: 15–28.
31. Gilbert D, Franko B, Ward J, Woodward G, Courtney K. Toxicologic studies of fenfluramine. Toxicol Appl Pharmacol. 1971;19: 705–711.
32. Borroni E, Ceci A, Garattini S, Mennini T. Differences between d-fenfluramine and d-norfenfluramine in serotonin presynaptic mechanism. J Neurochem. 1983;40: 891–893.
33. Cleinschmidt B, McGuffin J. Pharmacological differentiation of the central 5-hydroxtryptamine—like actions of MD-212, p-methocyamphetamine, and fenfluramine in an in vivo model system. Eur J Pharmacol. 1978;50:369.
34. Costa E, Gropetti A, Revuelta A. Action of fenfluramine on monoamine stores of rat tissue. Br J Pharmacol. 1971;41: 57–64.
35. Garrattini S, Buczko W, Jori A, Saminin R. The mechanism of action of fenfluramine. Postgrad Med J. 1975;51(suppl): 27–35.
36. Reuter C. A review of the CNS effects of fenfluramine, and norfenfluramine on animals and man. Postgrad Med J. 1975;51(suppl): 18–27.
37. Chouinard F, Goodman W, Greist J, Jenike M, Rasmussen S, White K, Hackett E, Gaffrey M, Bick P. Results of a double-blind controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull. 1990;26: 270–284.
38. Holland H. Displacement activity as a form of abnormal behavior in animals. In: Beech H, ed. Obsessional States. London, England: Methuen & Co Ltd; 1974: 161–173.
39. McKinney W, Bunney W. Animal models of depression: review of evidence and implications for research. Arch Gen Psychiatry. 1969;21: 240–248.
40. Wilner P. Validation criteria for animal models of human mental disorders: learned helplessness as a paradigm case. Prog Neuropsychopharmacol Biol Psychiatry. 1986;10: 677–690.
41. Dodman N, Shuster L, White S, Court M, Parker D, Dixon R. Use of narcotic antagonists to modify stereotypic self-lick, self-chewing, and scratching behavior in dogs. J Am Vet Med Assoc. 1988;193: 815–819.
42. Insel T, Pickar D. Naloxone administration in obsessive-compulsive disorder: report of two cases. Am J Psychiatry. 1983; 80: 1219–1220.
43. Sandyk R. Naloxone obliterates obsessive-compulsive disorder in Tourette's syndrome. Int J Neurosci. 1987;35: 93–94.
44. Goodman W, McDougle C, Price L, Riddle M, Pauls D, Leckman J. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive-compulsive disorder? J Clin Psychiatry. 1990;51(suppl 8): 36–43.
45. Lucki I, Kucharick R. Selective enhancement of grooming behavior by the D-1 agonist SKF 3893 in rats following the destruction of serotonin neurons. Ann NY Acad Sci. 1988;525: 420–422.
46. Joffe R, Swinson R. Methylphenidate in primary obsessive-compulsive disorder. J Clin Psychopharmacol. 1987;7: 420–422.
47. Insel T, Hamilton J, Guttmacher L, Murphy D. D-Amphetamine in obsessive-compulsive disorder. Psychopharmacology (Berl). 1983;80: 231–235.
48. Henn F, McKinney W. Animal models in psychiatry. In: Meltzer H, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987: 687–696.